Advertisement

Mesothelioma pp 261-269 | Cite as

Mesothelin-Targeted Agents in Mesothelioma

  • Loredana Urso
  • Giulia PaselloEmail author
Chapter

Abstract

Mesothelin (MSLN) is a cell surface glycoprotein expressed by mesothelial cells of the pleural, peritoneum, and pericardium. Its function in promoting tumor growth and its overexpression in malignant mesothelioma make this protein as a promising target for treatment of affected patients. Several treatment strategies have been explored in latest years. SS1P immunotoxin has the main limitation of early serum neutralizing antibodies production, thus leading to immunotoxin combinations and new-generation immunotoxins currently under investigation. Among mesothelin-targeted antibodies, both monoclonal antibodies such as amatuximab and antibody–drug conjugates such as anetumab–ravtansine are currently under investigation in combination with the standard of care platinum-based doublet plus pemetrexed chemotherapy. Anti-mesothelin vaccines and intrapleural administration of CAR-T meso therapies represent promising future strategies for malignant pleural mesothelioma patients even though these deserve further investigation.

Keywords

Mesothelin Targeted therapies Immunotoxin Antibodies Vaccine CAR T 

References

  1. 1.
    Pastan I, Hassan R. Discovery of mesothelin and exploiting it as a target for immunotherapy. Cancer Res. 2014;74(11):2907–12.CrossRefGoogle Scholar
  2. 2.
    Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, Takeuchi M, et al. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem. 2004;279(10):9190–8.CrossRefGoogle Scholar
  3. 3.
    Gubbels JA, Belisle J, Onda M, Rancourt C, Migneault M, Ho M, et al. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer. 2006;5(1):50.CrossRefGoogle Scholar
  4. 4.
    Tang Z, Qian M, Ho M. The role of mesothelin in tumor progression and targeted therapy. Anti Cancer Agents Med Chem. 2013;13(2):276–80.CrossRefGoogle Scholar
  5. 5.
    Bharadwaj U, Marin-Muller C, Li M, Chen C, Yao Q. Mesothelin overexpression promotes autocrine IL-6/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation. Carcinogenesis. 2011;32(7):1013–24.CrossRefGoogle Scholar
  6. 6.
    Bharadwaj U, Li M, Chen C, Yao Q. Mesothelin-induced pancreatic cancer cell proliferation involves alteration of cyclin E via activation of signal transducer and activator of transcription protein 3. Mol Cancer Res. 2008;6(11):1755–65.CrossRefGoogle Scholar
  7. 7.
    Bharadwaj U, Marin-Muller C, Li M, Chen C, Yao Q. Mesothelin confers pancreatic cancer cell resistance to TNF-alpha-induced apoptosis through Akt/PI3K/NF-kappaB activation and IL-6/Mcl-1 overexpression. Mol Cancer. 2011;10:106.CrossRefGoogle Scholar
  8. 8.
    Uehara N, Matsuoka Y, Tsubura A. Mesothelin promotes anchorage-independent growth and prevents anoikis via extracellular signal-regulated kinase signaling pathway in human breast cancer cells. Mol Cancer Res. 2008;6(2):186–93.CrossRefGoogle Scholar
  9. 9.
    Cheng WF, Huang CY, Chang MC, Hu YH, Chiang YC, Chen YL, et al. High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma. Br J Cancer. 2009;100(7):1144–53.CrossRefGoogle Scholar
  10. 10.
    Baldo P, Cecco S. Amatuximab and novel agents targeting mesothelin for solid tumors. OncoTargets Ther. 2017;10:5337–53.CrossRefGoogle Scholar
  11. 11.
    Creaney J, Francis RJ, Dick IM, Musk AW, Robinson BW, Byrne MJ, et al. Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden. Clin Cancer Res. 2011;17(5):1181–9.CrossRefGoogle Scholar
  12. 12.
    Servais EL, Colovos C, Rodriguez L, Bograd AJ, Nitadori J, Sima C, et al. Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients. Clin Cancer Res. 2012;18(9):2478–89.CrossRefGoogle Scholar
  13. 13.
    He X, Wang L, Riedel H, Wang K, Yang Y, Dinu CZ, et al. Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells. Mol Cancer. 2017;16(1):63.CrossRefGoogle Scholar
  14. 14.
    Melaiu O, Stebbing J, Lombardo Y, Bracci E, Uehara N, Bonotti A, et al. MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma. PLoS One. 2014;9(1):e85935.CrossRefGoogle Scholar
  15. 15.
    Forest F, Patoir A, Dal Col P, Sulaiman A, Camy F, Laville D, et al. Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications. Pathology. 2018;50(6):635–41.CrossRefGoogle Scholar
  16. 16.
    Chowdhury PS, Viner JL, Beers R, Pastan I. Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity. Proc Natl Acad Sci U S A. 1998;95(2):669–74.CrossRefGoogle Scholar
  17. 17.
    Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler H, Willingham MC, et al. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res. 2007;13(17):5144–9.CrossRefGoogle Scholar
  18. 18.
    Kreitman RJ, Hassan R, Fitzgerald DJ, Pastan I. Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin Cancer Res. 2009;15(16):5274–9.CrossRefGoogle Scholar
  19. 19.
    Zhang Y, Xiang L, Hassan R, Paik CH, Carrasquillo JA, Jang BS, et al. Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing mice. Clin Cancer Res. 2006;12(15):4695–701.CrossRefGoogle Scholar
  20. 20.
    Hassan R, Sharon E, Thomas A, Zhang J, Ling A, Miettinen M, et al. Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125. Cancer. 2014;120(21):3311–9.CrossRefGoogle Scholar
  21. 21.
    Hassan R, Miller AC, Sharon E, Thomas A, Reynolds JC, Ling A, et al. Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. Sci Transl Med. 2013;5(208):208ra147.CrossRefGoogle Scholar
  22. 22.
    Liu W, Onda M, Lee B, Kreitman RJ, Hassan R, Xiang L, et al. Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes. Proc Natl Acad Sci U S A. 2012;109(29):11782–7.CrossRefGoogle Scholar
  23. 23.
    Zhang J, Khanna S, Jiang Q, Alewine C, Miettinen M, Pastan I, et al. Efficacy of anti-mesothelin immunotoxin RG7787 plus nab-paclitaxel against mesothelioma patient-derived xenografts and mesothelin as a biomarker of tumor response. Clin Cancer Res. 2017;23(6):1564–74.CrossRefGoogle Scholar
  24. 24.
    Hassan R, Ebel W, Routhier EL, Patel R, Kline JB, Zhang J, et al. Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. Cancer Immun. 2007;7:20.PubMedPubMedCentralGoogle Scholar
  25. 25.
    Lindenberg L, Thomas A, Adler S, Mena E, Kurdziel K, Maltzman J, et al. Safety and biodistribution of 111In-amatuximab in patients with mesothelin expressing cancers using single photon emission computed tomography-computed tomography (SPECT-CT) imaging. Oncotarget. 2015;6(6):4496–504.CrossRefGoogle Scholar
  26. 26.
    Hassan R, Cohen SJ, Phillips M, Pastan I, Sharon E, Kelly RJ, et al. Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. Clin Cancer Res. 2010;16(24):6132–8.CrossRefGoogle Scholar
  27. 27.
    Fujisaka Y, Kurata T, Tanaka K, Kudo T, Okamoto K, Tsurutani J, et al. Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors. Investig New Drugs. 2015;33(2):380–8.CrossRefGoogle Scholar
  28. 28.
    Hassan R, Kindler HL, Jahan T, Bazhenova L, Reck M, Thomas A, et al. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014;20(23):5927–36.CrossRefGoogle Scholar
  29. 29.
    Golfier S, Kopitz C, Kahnert A, Heisler I, Schatz CA, Stelte-Ludwig B, et al. Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect. Mol Cancer Ther. 2014;13(6):1537–48.CrossRefGoogle Scholar
  30. 30.
    Kovtun YV, Audette CA, Ye Y, Xie H, Ruberti MF, Phinney SJ, et al. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res. 2006;66(6):3214–21.CrossRefGoogle Scholar
  31. 31.
    Blumenschein GR, Hassan R, Moore KN, Santin A, Kindler HL, Nemunaitis JJ, et al. Phase I study of anti-mesothelin antibody drug conjugate anetumab ravtansine (AR). J Clin Oncol. 2016;34(15_suppl):2509.CrossRefGoogle Scholar
  32. 32.
    Kindler HL, Novello S, Fennell D, Blumenschein G, Bearz A, Ceresoli G, et al. OA 02.01 randomized phase II study of anetumab ravtansine or vinorelbine in patients with metastatic pleural mesothelioma. J Thorac Oncol. 2017;12(11):S1746.CrossRefGoogle Scholar
  33. 33.
    Zhang C, Liu J, Zhong JF, Zhang X. Engineering CAR-T cells. Biomarker Res. 2017;5:22.CrossRefGoogle Scholar
  34. 34.
    Morello A, Sadelain M, Adusumilli PS. Mesothelin-targeted CARs: driving T cells to solid tumors. Cancer Discov. 2016;6(2):133–46.CrossRefGoogle Scholar
  35. 35.
    Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res. 2014;2(2):112–20.CrossRefGoogle Scholar
  36. 36.
    Adusumilli PS, Cherkassky L, Villena-Vargas J, Colovos C, Servais E, Plotkin J, et al. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci Transl Med. 2014;6(261):261ra151.CrossRefGoogle Scholar
  37. 37.
    Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011;365(18):1673–83.CrossRefGoogle Scholar
  38. 38.
    Brockstedt DG, Giedlin MA, Leong ML, Bahjat KS, Gao Y, Luckett W, et al. Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proc Natl Acad Sci U S A. 2004;101(38):13832–7.CrossRefGoogle Scholar
  39. 39.
    Le DT, Brockstedt DG, Nir-Paz R, Hampl J, Mathur S, Nemunaitis J, et al. A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction. Clin Cancer Res. 2012;18(3):858–68.CrossRefGoogle Scholar
  40. 40.
    Jahan T, Hassan R, Alley E, Kindler H, Antonia S, Whiting C, et al. 208O_PR: CRS-207 with chemotherapy (chemo) in malignant pleural mesothelioma (MPM): results from a phase 1b trial. J Thorac Oncol. 2016;11(4):S156.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Surgery, Oncology and GastroenterologyUniversity of PadovaPadovaItaly
  2. 2.Medical Oncology 2, Istituto Oncologico Veneto IRCCSPadovaItaly

Personalised recommendations